Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMROZ: Isatuximab + VRd in Newly Diagnosed Multiple Myeloma
NCT03319667Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- Dec 2017
- Primary completion
- Apr 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 21
01
Overview
A Phase 3 trial of isatuximab in multiple myeloma (MM), sponsored by Sanofi. Started Dec 2017; status: active, not recruiting.
02
Drugs
isatuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03319667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03319667.